Last reviewed · How we verify

NCT05538403

AI Performance for the Detection of Bone Fractures in Children

Status unknown Last updated 13 September 2022
What this trial tests

trial in Fracture in 210 participants. Status unknown.

Timeline
1 May 2022
Primary endpoint
1 November 2022
30 December 2022

Quick facts

Lead sponsorUniversity Hospital, Montpellier
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment210
Start date1 May 2022
Primary completion1 November 2022
Estimated completion30 December 2022
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

Adults 0 to 2, any sex, with Fracture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The artificial intelligence (AI) software BoneView (GLEAMER Company, Paris, France) has been designed, tested and validated to detect and locate recent or semi-recent fractures on standard radiographs. The objective will be to assess the AI performance for the detection of bone fractures in children aged less than 2 years old in suspected child abuse setting. These patients benefit from a whole body radiography with a double blind reading by a "generalist" radiologist and a radiologist with expertise in child abuse. This readings will be compared with the AI results. Hypothesis is that AI is effective for child fractures detection and could be of help especially for radiologists who are not experts in child abuse.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fracture

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05538403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing